Tan WS, Tan WP, Tan MY, Khetrapal P, Dong L, deWinter P, et al. Novel urinary biomarkers for the detection of bladder cancer: A systematic review. Cancer Treat Rev. 2018 Sep. 69:39-52. [QxMD MEDLINE Link].
Ahn JH, Kang CK, Kim EM, Kim AR, Kim A. Proteomics for Early Detection of Non-Muscle-Invasive Bladder Cancer: Clinically Useful Urine Protein Biomarkers. Life (Basel). 2022 Mar 9. 12 (3):4935-43. [QxMD MEDLINE Link]. [Full Text].
Maas M, Bedke J, Stenzl A, Todenhöfer T. Can urinary biomarkers replace cystoscopy?. World J Urol. 2018 Oct 3. [QxMD MEDLINE Link].
Leiblich A. Recent Developments in the Search for Urinary Biomarkers in Bladder Cancer. Curr Urol Rep. 2017 Nov 13. 18 (12):100. [QxMD MEDLINE Link]. [Full Text].
Halling KC, King W, Sokolova IA, Karnes RJ, Meyer RG, Powell EL, et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol. 2002 May. 167(5):2001-6. [QxMD MEDLINE Link].
Urquidi V, Goodison S, Ross S, Chang M, Dai Y, Rosser CJ. Diagnostic potential of urinary a1-antitrypsin and apolipoprotein E in the detection of bladder cancer. J Urol. 2012 Dec. 188(6):2377-83. [QxMD MEDLINE Link].
Miyake M, Goodison S, Rizwani W, Ross S, Bart Grossman H, Rosser CJ. Urinary BTA: indicator of bladder cancer or of hematuria. World J Urol. 2012 Dec. 30(6):869-73. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. 2020 Apr 29. [QxMD MEDLINE Link]. [Full Text].
Eissa S, Motawi T, Badr S, Zaghlool A, Maher A. Evaluation of urinary human telomerase reverse transcriptase mRNA and scatter factor protein as urine markers for diagnosis of bladder cancer. Clin Lab. 2013. 59(3-4):317-23. [QxMD MEDLINE Link].
Lozano F, Raventos CX, Carrion A, Trilla E, Morote J. Current status of genetic urinary biomarkers for surveillance of non-muscle invasive bladder cancer: a systematic review. BMC Urol. 2020 Jul 14. 20 (1):99. [QxMD MEDLINE Link]. [Full Text].
Laukhtina E, et al; European Association of Urology–Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. Eur Urol Oncol. 2021 Dec. 4 (6):927-942. [QxMD MEDLINE Link]. [Full Text].
Halling KC, King W, Sokolova IA, Meyer RG, Burkhardt HM, Halling AC, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol. 2000 Nov. 164(5):1768-75. [QxMD MEDLINE Link].
Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn. 2000 Aug. 2(3):116-23. [QxMD MEDLINE Link]. [Full Text].
Kamoun A, et al; Bladder Cancer Molecular Taxonomy Group. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2020 Apr. 77 (4):420-433. [QxMD MEDLINE Link]. [Full Text].
Veeramachaneni R, Nordberg ML, Shi R, Herrera GA, Turbat-Herrera EA. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma. Diagn Cytopathol. 2003 Jun. 28(6):301-7. [QxMD MEDLINE Link].
Skacel M, Fahmy M, Brainard JA, Pettay JD, Biscotti CV, Liou LS, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol. 2003 Jun. 169(6):2101-5. [QxMD MEDLINE Link].
Saad A, Hanbury DC, McNicholas TA, Boustead GB, Morgan S, Woodman AC. A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int. 2002 Mar. 89(4):369-73. [QxMD MEDLINE Link].
Laudadio J, Keane TE, Reeves HM, Savage SJ, Hoda RS, Lage JM, et al. Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int. 2005 Dec. 96(9):1280-5. [QxMD MEDLINE Link].
Berezney R, Coffey DS. Identification of a nuclear protein matrix. Biochem Biophys Res Commun. 1974 Oct 23. 60(4):1410-7. [QxMD MEDLINE Link].
Pardoll DM, Vogelstein B, Coffey DS. A fixed site of DNA replication in eucaryotic cells. Cell. 1980 Feb. 19(2):527-36. [QxMD MEDLINE Link].
Gordon JN, Shu WP, Schlussel RN, Droller MJ, Liu BC. Altered extracellular matrices influence cellular processes and nuclear matrix organizations of overlying human bladder urothelial cells. Cancer Res. 1993 Oct 15. 53(20):4971-7. [QxMD MEDLINE Link].
Keesee SK, Briggman JV, Thill G, Wu YJ. Utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukaryot Gene Expr. 1996. 6(2-3):189-214. [QxMD MEDLINE Link].
Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA. 2006 Jan 18. 295(3):299-305. [QxMD MEDLINE Link].
Konety BR. Molecular markers in bladder cancer: a critical appraisal. Urol Oncol. 2006 Jul-Aug. 24(4):326-37. [QxMD MEDLINE Link].
Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I. Noninvasive detection of bladder cancer with the BTA stat test. J Urol. 1999 Feb. 161(2):443-6. [QxMD MEDLINE Link].
Greene KL, Berry A, Konety BR. Diagnostic Utility of the ImmunoCyt/uCyt+ Test in Bladder Cancer. Rev Urol. 2006 Fall. 8(4):190-7. [QxMD MEDLINE Link]. [Full Text].
Comploj E, Mian C, Ambrosini-Spaltro A, Dechet C, Palermo S, Trenti E, et al. uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma: an update on 7422 analyses. Cancer Cytopathol. 2013 Jul. 121(7):392-7. [QxMD MEDLINE Link].
van Oers JM, Lurkin I, van Exsel AJ, Nijsen Y, van Rhijn BW, van der Aa MN. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res. 2005 Nov 1. 11(21):7743-8. [QxMD MEDLINE Link].
Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, Van Rhijn B. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001 Jun. 158(6):1955-9. [QxMD MEDLINE Link].
van Rhijn BW, van Tilborg AA, Lurkin I, Bonaventure J, de Vries A, Thiery JP. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet. 2002 Dec. 10(12):819-24. [QxMD MEDLINE Link].
van Oers JM, Zwarthoff EC, Rehman I, Azzouzi AR, Cussenot O, Meuth M, et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol. 2009 Mar. 55(3):650-7. [QxMD MEDLINE Link].
Millholland JM, Li S, Fernandez CA, Shuber AP. Detection of low frequency FGFR3 mutations in the urine of bladder cancer patients using next-generation deep sequencing. Res. Reports Urol. June 2012. 4:33-40.
Karnes RJ, Fernandez CA, Shuber AP. A noninvasive multianalyte urine-based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuria. Mayo Clin Proc. 2012 Sep. 87(9):835-42. [QxMD MEDLINE Link].
Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J, et al. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol. 2011 Sep. 60(3):484-92. [QxMD MEDLINE Link].
O'Sullivan P, Sharples K, Dalphin M, Davidson P, Gilling P, Cambridge L. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol. 2012 Sep. 188(3):741-7. [QxMD MEDLINE Link].
Xpert® Bladder Cancer Detection. Cepheid. Available at https://www.cepheid.com/en/tests/Oncology-Genetics/Xpert-Bladder-Cancer-Detection. Accessed: November 9, 2022.
Cowan B, Klein E, Jansz K, et al. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert® Bladder Cancer Monitor ) for surveillance in patients with non-muscle-invasive bladder cancer. BJU Int. 2021 Dec. 128 (6):713-721. [QxMD MEDLINE Link]. [Full Text].
Horstmann M, Patschan O, Hennenlotter J, Senger E, Feil G, Stenzl A. Combinations of urine-based tumour markers in bladder cancer surveillance. Scand J Urol Nephrol. 2009. 43(6):461-6. [QxMD MEDLINE Link].
Todenhöfer T, Hennenlotter J, Esser M, Mohrhardt S, Tews V, Aufderklamm S. Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma. Cancer Cytopathol. 2013 May. 121(5):252-60. [QxMD MEDLINE Link].
Black PC, Brown GA, Dinney CP. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol. 2006 Dec 10. 24(35):5528-35. [QxMD MEDLINE Link].
Goodison S, Rosser CJ, Urquidi V. Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests. Mol Diagn Ther. 2013 Apr. 17(2):71-84. [QxMD MEDLINE Link]. [Full Text].
Wadhwa N, Jatawa SK, Tiwari A. Republished: non-invasive urine based tests for the detection of bladder cancer. Postgrad Med J. 2013 Jun. 89(1052):352-7. [QxMD MEDLINE Link].
Tölle A, Jung M, Rabenhorst S, Kilic E, Jung K, Weikert S. Identification of microRNAs in blood and urine as tumour markers for the detection of urinary bladder cancer. Oncol Rep. 2013 Oct. 30(4):1949-56. [QxMD MEDLINE Link].
Jazayeri MH, Aghaie T, Nedaeinia R, Manian M, Nickho H. Rapid noninvasive detection of bladder cancer using survivin antibody-conjugated gold nanoparticles (GNPs) based on localized surface plasmon resonance (LSPR). Cancer Immunol Immunother. 2020 Apr 30. [QxMD MEDLINE Link].
Song Y, Jin D, Ou N, Luo Z, Chen G, Chen J, et al. Gene Expression Profiles Identified Novel Urine Biomarkers for Diagnosis and Prognosis of High-Grade Bladder Urothelial Carcinoma. Front Oncol. 2020. 10:394. [QxMD MEDLINE Link]. [Full Text].
Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019 Mar. 17:100087. [QxMD MEDLINE Link]. [Full Text].
Ge G, Peng D, Guan B, Zhou Y, Gong Y, Shi Y, et al. Urothelial Carcinoma Detection Based on Copy Number Profiles of Urinary Cell-Free DNA by Shallow Whole-Genome Sequencing. Clin Chem. 2019 Dec 6. [QxMD MEDLINE Link].
Ou Z, Li K, Yang T, Dai Y, Chandra M, Ning J, et al. Detection of bladder cancer using urinary cell-free DNA and cellular DNA. Clin Transl Med. 2020 Jan 14. 9 (1):4. [QxMD MEDLINE Link]. [Full Text].
Shariat SF, Marberger MJ, Lotan Y, Sanchez-Carbayo M, Zippe C, Lüdecke G, et al. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol. 2006 Sep. 176(3):919-26; discussion 926. [QxMD MEDLINE Link].
Rizzoli G, Mazzucco A, Brumana T, Stellin G, Livi U, fa*ggian G, et al. The risk of surgical treatment of tetralogy of Fallot: an appraisal. Int J Cardiol. 1985 Sep. 9(1):7-26. [QxMD MEDLINE Link].
van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol. 2005 Jun. 47(6):736-48. [QxMD MEDLINE Link].
Mbeutcha A, Lucca I, Mathieu R, Lotan Y, Shariat SF. Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer. Urol Clin North Am. 2016 Feb. 43 (1):47-62. [QxMD MEDLINE Link].
Chou R, Gore JL, Buckley D, Fu R, Gustafson K, Griffin JC, et al. Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis. Ann Intern Med. 2015 Dec 15. 163 (12):922-31. [QxMD MEDLINE Link]. [Full Text].
FAQs
What are the markers for bladder cancer in urine? ›
Urine tumor marker tests
One or more of these tests may be used along with urine cytology to help see if you have bladder cancer. These include the tests called NMP22® (or BladderChek®), BTA Stat®, Immunocyt® , and UroVysion®, which are discussed in Can Bladder Cancer Be Found Early?
BTA tests: These tests look for a substance called bladder tumor-associated antigen (BTA), also known as CFHrp, in the urine. ImmunoCyt™: This test looks at cells in the urine for the presence of substances such as mucin and carcinoembryonic antigen (CEA), which are often found on cancer cells.
What are the genetic markers for bladder cancer? ›Somatic mutations in the FGFR3, PIK3CA, KDM6A, and TP53 genes are common in bladder cancers. Each of these genes plays a critical role in regulating gene activity and cell growth, ensuring cells do not grow and divide too rapidly or uncontrollably.
What is the gold standard diagnostic test for bladder cancer? ›Cystoscopy is the key diagnostic procedure for bladder cancer. It allows the doctor to see inside the body with a thin, lighted, flexible tube called a cystoscope. Flexible cystoscopy is performed in a doctor's office and does not require anesthesia, which is medication that blocks the awareness of pain.
What is the most accurate test for bladder cancer? ›- The most efficient, noninvasive and inexpensive test is a urinalysis/cytology. ...
- If abnormalities are found in the urine, a biopsy will be performed, in which a pathologist examines tissue for the presence of cancer cells.
Urine cytology is still the most accurate noninvasive test for bladder cancer that is in routine clinical use, with a sensitivity of 80–90% and a specificity of 98–100% for detection of high-grade lesions and carcinoma in situ (CIS).
How long can you have bladder cancer without knowing? ›Can bladder cancer go undetected for years? If symptoms such as blood in the urine and changes in urinary habits are ignored by an individual and/or repeatedly misdiagnosed, it's possible that bladder cancer may not be detected for months or, in some cases, even years.
What does Stage 1 bladder cancer feel like? ›The first sign of bladder cancer is blood in the urine, which is painless for most people. In the early stages, this may be your only symptom, though some people don't experience it. Other symptoms include changes in bladder habits, frequent urinary infections, and pelvic or back pain, which might be on one side.
What Colour is urine with bladder cancer? ›The symptoms of bladder cancer can vary from person to person. The most common symptom is blood in the urine, called hematuria. It's often slightly rusty to bright red in color. You may see blood in your urine at one point, then not see it again for a while.
What is the most common mutation in bladder cancer? ›The bladder cancer studies have suggested that 70 % of bladder cancers involve a specific mutation in a particular gene, namely telomerase reverse transcriptase (TERT) gene. The TERT gene is involved in DNA protection, cellular aging processes, and cancer.
What are the 3 types of bladder cancer? ›
- Urothelial carcinoma. Urothelial carcinoma (or UCC) accounts for about 90% of all bladder cancers. ...
- Squamous cell carcinoma. Squamous cells develop in the bladder lining in response to irritation and inflammation. ...
- Adenocarcinoma.
Cystoscopy helps to diagnose, and sometimes treat, bladder cancer and other conditions. Cystoscopy. A cystoscope (a thin, tube-like instrument with a light and a lens for viewing) is inserted through the urethra into the bladder. Fluid is used to fill the bladder.
What does bladder cancer look like on a cystoscopy? ›CIS: Carcinoma in situ (CIS) is often seen as a red, velvety patch in the bladder. This type of cancer grows on the surface of the bladder. It has a high risk of changing into disease that can invade into the muscle of the bladder wall.
What are the symptoms of bladder cancer in a woman? ›- Blood in urine (hematuria), which may cause urine to appear bright red or cola colored, though sometimes the urine appears normal and blood is detected on a lab test.
- Frequent urination.
- Painful urination.
- Back pain.
Bladder cancer is sometimes called a "silent killer" since it can develop without showing signs until it gets further along. This implies that early recognition and knowledge are key in treating this illness well.
Does bladder cancer show up in a urine culture? ›Notably, although urinalysis and urine culture are relevant steps in the process of bladder cancer diagnosis, these tests cannot determine the presence (or absence) of bladder cancer. Urine cytology refers to the microscopic examination of cells from urine samples.
Can a urine dipstick test detect cancer? ›The high specificity of dipstick urinalysis may provide benefit when used as an inexpensive test to rule out microhematuria or bladder cancer in patients. However the low sensitivity limits its utility as a screening test.
Can you have bladder cancer with clear urine? ›You could even have clear urine for months. It is not common to experience other symptoms at this early stage of bladder cancer.